PL4269444T3 - Wieloswoiste przeciwciała anty-tcr zmienne delta 1 - Google Patents

Wieloswoiste przeciwciała anty-tcr zmienne delta 1

Info

Publication number
PL4269444T3
PL4269444T3 PL23187269.8T PL23187269T PL4269444T3 PL 4269444 T3 PL4269444 T3 PL 4269444T3 PL 23187269 T PL23187269 T PL 23187269T PL 4269444 T3 PL4269444 T3 PL 4269444T3
Authority
PL
Poland
Prior art keywords
tcr antibodies
multispecific anti
variable delta
antibodies variable
delta
Prior art date
Application number
PL23187269.8T
Other languages
English (en)
Polish (pl)
Inventor
Mark Uden
Mihriban Tuna
Natalie MOUNT
Robert Good
Joshua Freedman
Shefali BHUMBRA
Oliver Nussbaumer
Raj Jaysukhlal MEHTA
Original Assignee
GammaDelta Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4269444(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Application filed by GammaDelta Therapeutics Limited filed Critical GammaDelta Therapeutics Limited
Publication of PL4269444T3 publication Critical patent/PL4269444T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
PL23187269.8T 2020-08-14 2021-08-14 Wieloswoiste przeciwciała anty-tcr zmienne delta 1 PL4269444T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies

Publications (1)

Publication Number Publication Date
PL4269444T3 true PL4269444T3 (pl) 2025-01-13

Family

ID=80247426

Family Applications (2)

Application Number Title Priority Date Filing Date
PL23187269.8T PL4269444T3 (pl) 2020-08-14 2021-08-14 Wieloswoiste przeciwciała anty-tcr zmienne delta 1
PL21756070.5T PL4010082T5 (pl) 2020-08-14 2021-08-14 Wieloswoiste przeciwciała anty-tcr zmienne delta 1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21756070.5T PL4010082T5 (pl) 2020-08-14 2021-08-14 Wieloswoiste przeciwciała anty-tcr zmienne delta 1

Country Status (18)

Country Link
EP (7) EP4265642B1 (https=)
JP (1) JP7847579B2 (https=)
KR (1) KR20230083267A (https=)
CN (1) CN116209456A (https=)
AU (1) AU2021323512A1 (https=)
BR (1) BR112023002741A2 (https=)
CA (1) CA3188682A1 (https=)
CO (1) CO2023003009A2 (https=)
DK (2) DK4010082T4 (https=)
ES (2) ES2943063T3 (https=)
FI (2) FI4010082T4 (https=)
IL (1) IL300517A (https=)
LT (2) LT4010082T (https=)
MX (1) MX2023001728A (https=)
PL (2) PL4269444T3 (https=)
PT (2) PT4010082T (https=)
SI (2) SI4010082T1 (https=)
WO (1) WO2022034562A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
WO2023250485A1 (en) * 2022-06-23 2023-12-28 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
WO2024193459A1 (en) * 2023-03-17 2024-09-26 Nanjing Legend Biotech Co., Ltd. METHODS OF CULTURING Vδ1 T CELLS
WO2025147597A1 (en) * 2024-01-05 2025-07-10 Eugit Therapeutics, Inc. Targeting payloads
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP3344658B1 (en) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
WO2017072367A1 (en) 2015-10-30 2017-05-04 Cancer Research Technology Limited EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US20180028566A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
EP3645050A4 (en) 2017-06-25 2021-08-11 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
AU2019344300A1 (en) * 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
US12084500B2 (en) * 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
CA3136251A1 (en) 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ Ｔ細胞集団
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
AU2022224391A1 (en) 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies

Also Published As

Publication number Publication date
EP4269446B1 (en) 2024-06-26
EP4265643B1 (en) 2024-06-26
JP7847579B2 (ja) 2026-04-17
AU2021323512A1 (en) 2023-04-13
PT4269444T (pt) 2024-09-05
EP4010082A1 (en) 2022-06-15
LT4010082T (lt) 2023-03-10
ES2993071T3 (en) 2024-12-20
DK4269444T3 (en) 2024-08-19
EP4265643A2 (en) 2023-10-25
FI4010082T4 (fi) 2026-03-24
EP4265642B1 (en) 2024-06-26
FI4010082T3 (fi) 2023-04-04
EP4218932A2 (en) 2023-08-02
EP4269446A3 (en) 2024-02-14
PL4010082T5 (pl) 2026-03-09
DK4010082T5 (da) 2024-08-05
CA3188682A1 (en) 2022-02-17
EP4265643A3 (en) 2024-02-14
EP4010082B2 (en) 2025-12-31
PL4010082T3 (pl) 2023-05-29
CO2023003009A2 (es) 2023-03-17
SI4269444T1 (sl) 2024-10-30
EP4265642A3 (en) 2024-02-14
EP4010082B1 (en) 2023-01-25
FI4269444T3 (fi) 2024-09-20
DK4269444T5 (da) 2024-08-26
ES2943063T3 (es) 2023-06-08
EP4218932A3 (en) 2023-09-27
LT4269444T (lt) 2024-09-25
EP4265642A2 (en) 2023-10-25
EP4269444A3 (en) 2024-02-14
WO2022034562A1 (en) 2022-02-17
DK4010082T3 (da) 2023-04-03
KR20230083267A (ko) 2023-06-09
EP4269445B1 (en) 2024-06-26
SI4010082T1 (sl) 2023-04-28
DK4010082T4 (en) 2026-02-16
EP4269445A2 (en) 2023-11-01
BR112023002741A2 (pt) 2023-10-10
EP4010082B9 (en) 2026-03-04
EP4269444B1 (en) 2024-06-26
MX2023001728A (es) 2023-04-20
IL300517A (en) 2023-04-01
EP4269444A2 (en) 2023-11-01
EP4269446A2 (en) 2023-11-01
EP4269445A3 (en) 2024-02-14
JP2023537534A (ja) 2023-09-01
CN116209456A (zh) 2023-06-02
PT4010082T (pt) 2023-04-26

Similar Documents

Publication Publication Date Title
PL4269444T3 (pl) Wieloswoiste przeciwciała anty-tcr zmienne delta 1
IL290537A (en) Therapeutic uses of anti-tcr delta variable 1 antibodies
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
DK4214240T3 (da) Anti-ccr8-antistoffer
IL311043A (en) Anti-il-11rα antibodies
IL310245A (en) Anti-hla-g antibodies
EP4392455A4 (en) ANTI-CD-25 ANTIBODIES
ZA202308120B (en) Multispecific anti-tcr delta variable 1 antibodies
DK4172199T3 (da) Alfa-synuklein-protofibril-bindende antistoffer
EP4431606A4 (en) ANTI-EPHA4 ANTIBODIES
EP4323408A4 (en) NEW ANTI-HVEGFR2 ANTIBODIES
GB202111685D0 (en) Anti-tcr delta variable 1 antibodies
EP4311082A4 (en) COMPONENT
GB202102222D0 (en) Multispecific anti-TCR delta variable 1 antibodies
ES1255385Y (es) Bandeja
HK40104958A (en) Multispecific anti-tcr delta variable 1 antibodies
EP4342989A4 (en) ANTI-NOROVIRUS ANTIBODIES
EP4419567A4 (en) MULTI-SPECIFIC ANTI-TSHR ANTIBODIES AND THEIR USES
EP4453327C0 (de) Schnellwechsler
JP1761938S (ja) ノート
JP1761937S (ja) ノート
EP4471096A4 (en) MOLDED ITEM
EP4519356A4 (en) MOLDED ITEM
CA210249S (fr) Balance
CA210250S (fr) Balance